US 12,247,019 B2
Inhibitors of dihydroceramide desaturase for treating disease
Donna L. Romero, San Francisco, CA (US); and Jeremy Blitzer, San Francisco, CA (US)
Assigned to Centaurus Therapeutics, Half Moon Bay, CA (US)
Filed by Centaurus Therapeutics, Half Moon Bay, CA (US)
Filed on Feb. 6, 2023, as Appl. No. 18/106,305.
Application 18/106,305 is a continuation of application No. 16/959,807, granted, now 11,597,715, previously published as PCT/US2019/013193, filed on Jan. 11, 2019.
Claims priority of provisional application 62/616,253, filed on Jan. 11, 2018.
Prior Publication US 2023/0357187 A1, Nov. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/12 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); C07D 213/75 (2006.01); C07D 213/76 (2006.01); C07D 241/04 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 405/12 (2006.01)
CPC C07D 401/12 (2013.01) [C07D 213/75 (2013.01); C07D 213/76 (2013.01); C07D 241/04 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/12 (2013.01); A61K 9/0053 (2013.01); A61K 45/06 (2013.01)] 31 Claims
 
1. A method of treating a Des1-mediated disorder in a subject in need thereof, comprising the step of administering to the subject a compound of structural Formula II

OG Complex Work Unit Chemistry
or a salt thereof, wherein:
W is —NH—;
X is N;
Y is chosen from CH and N;
R5 is chosen from alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, (aryl) alkyl, (heteroaryl) alkyl, (aryl) aryl, (heteroaryl) aryl, (aryl) heteroaryl, and (heteroaryl) heteroaryl, and is optionally substituted with 1, 2, or 3 R6 groups; and
each R6 is independently chosen from alkoxy, alkyl, amino, carboxy, cyano, halo, haloalkoxy, and hydroxy; and
n is chosen from 1 and 2.